NOW VIRTUAL: Duke Debates Hematologic Malignancies (8.14.20)
Update as of July 17, 2020: This event is now virtual
The 21st Annual Duke Debates conference on "Controversies in the Management of Hematologic Malignancies," presented by the Duke Cancer Network in collaboration with Duke Cancer Institute, will be held Friday, Aug. 14 in a virtual format.
The program chair and one of the Duke speakers is David Rizzieri, MD.
Duke speakers include Ahmed Galal, MD, Lindsay Rein, MD, Jie Wang, MD, Matthew McKinney, MD, Andrea Sitlinger, MD, Christopher Kelsey, MD, John J. Strouse, MD, PhD, and Nirmish Shah, MD.
Honored guest faculty speakers include Daniel DeAngelo, MD, PhD (DFCI), Ronan Swords, MD (AbbVie), Wendy Stock, MD (Chicago), Anjali Advani, MD (Cleveland Clinic), Josef Prchal, MD (Utah), Jonathon Cohen, MD, MS (Emory), and John Pagel, MD, PhD (SCI).
This educational program is directed toward oncologists, hematologists, pharmacists, pharmacy technicians, nurse practitioners, physician assistants, fellows, nurses and other health care professionals. The purpose of this conference is to educate oncologists, hematologists, and the healthcare team regarding evolving and contemporary standards of care for the optimal treatments of patients with hematologic malignancies.
Practical issues, current standards, and controversies in the management of these diseases will be discussed in debates, traditional lectures and tumor boards.
Topics include treatment management of AML in patients over 60 years old, AYA patients with BCR/ABL negative ALL, PV patients, patients with stage 1 mantle cell lymphoma, patients with relapsed mantle cell lymphoma, and CLL patients.
The use of CAR-T and other immunotherapies in the mangement of acute and late toxicities will also be debated, the role of the Molecular Tumor Board in hematologic malignancies, and the use of novel therapies in Sickle Cell disease will also be discussed.